Abstract: Allergic diseases are inflammatory diseases that cause tissue inflammation or organ dysfunction due to abnormal immune response to allergens，and the global health burden is huge， severely affecting the quality of life of the children.Despite great progress in the understanding of allergic diseases in recent years，especially bronchial asthma， it is found that there are significant differences in clinical characteristics（phenotype），treatment response，or disease progression in many children receiving conventional treatment.With the latest understanding of the pathophysiology of bronchial asthma，biologics provide new therapeutic strategies for severe，and also provide new approach difficult-to-control airway allergic diseases and prevent disease progression.Most of the current studies are conducted in bronchial asthma and show encouraging results.This article summarizes the clinical progress of the application of biologics in children’s bronchial asthma and provides clinicians with relevant application information.

Key words:

摘要： 过敏性疾病是机体对过敏原的异常免疫反应而导致组织炎症或器官功能障碍的炎症性疾病，其带来的全球健康负担很大，严重影响患儿的生活质量。尽管近年来对过敏性疾病的认识取得了很大的进步，尤其是在支气管哮喘方面。但是仍发现许多常规治疗的患儿中，临床特征（表型），治疗反应或疾病进程存在显著差异。随着对支气管哮喘的病理生理机制的最新认识，生物制剂为重症及难控制的气道过敏性疾病提供了新的治疗策略并为预防疾病的进展提供了新途径。目前大多数研究是在支气管哮喘中进行的，且表现出令人鼓舞的结果。该文总结了有关生物制剂在儿童支气管哮喘应用的临床进展，为临床医生提供相关应用信息。

关键词: